Tacrolimus capsule
Sponsors
Astellas Pharma Inc, Oslo University Hospital, Hanlim Pharm. Co., Ltd., Edward Geissler, Johns Hopkins University
Conditions
Healthy Male VolunteersImmune SuppressionImmunosuppressionKidney Transplant; ComplicationsLupus NephritisMyasthenia GravisPost-ERCP Acute PancreatitisProphylaxis Against Liver Transplant Rejection
Phase 1
Phase 3
A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis
CompletedNCT01325571
Start: 2011-03-31End: 2014-05-31Updated: 2016-03-09
A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients
TerminatedNCT01342016
Start: 2011-04-30End: 2013-05-31Updated: 2014-10-17
Rectal Indomethacin and Oral Tacrolimus Versus Combination to Prevent Post-ERCP Pancreatitis
RecruitingNCT05252754
Start: 2023-01-18End: 2026-12-31Target: 4874Updated: 2025-12-09
Phase 4
Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects
Active, not recruitingNCT04207177
Start: 2019-10-30End: 2025-12-31Target: 100Updated: 2024-04-04
Bioavailability and Practicability of Envarsus Versus Advagraf in Liver Transplant Recipients
Active, not recruitingNCT04720326
Start: 2020-12-23End: 2026-10-31Updated: 2025-04-06
Tacrolimus C:D Ratio Measured in Renal Transplant Recipients Treated With Once-daily Prolonged-release Drugs
RecruitingNCT06268769
Start: 2024-03-09End: 2029-09-30Target: 300Updated: 2024-05-16